Clinical Trial Update: "LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating LANK-2 NK cell immunotherapy with salvage chemotherapy in children, adolescents, and young adults with relapsed or refractory acute leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• LANK-2

Snippet

Sponsor: Hospital Universitario La Paz | Conditions: Relapsed/Refractory Paediatric Acute Leukaemia | Phase 2 | Status: COMPLETED